Deletions of LPL and NKX3.1 in Prostate Cancer Progression: Game Changers or By-Standers in Tumor Evolution

The tumor suppressor gene <i>NKX3</i>.1 and the <i>LPL</i> gene are located in close proximity on chromosome 8, and their deletion has been reported in multiple studies. However, the significance of <i>LPL</i> loss may be misinterpreted due to its co-deletion with <i>NKX3.1</i>, a well-established event in prostate carcinogenesis. This study investigates whether <i>LPL</i> deletion represents a biologically relevant event or occurs merely as a bystander to <i>NKX3.1</i> loss. We analyzed 28 formalin-fixed paraffin-embedded prostate cancer samples with confirmed <i>LPL</i> deletion and 28 without. Immunohistochemical staining was performed, and previously published whole-genome sequencing data from 103 prostate cancer patients were reanalyzed. Deletion of the 8p21.3 region was associated with higher Gleason grade groups. While NKX3.1 expression was significantly reduced in prostate cancer compared to benign prostatic hyperplasia, LPL protein expression showed no significant difference between cancerous and benign tissue, nor was it affected by the 8p21.3 deletion status. Copy number analysis confirmed the co-deletion of <i>NKX3.1</i> and <i>LPL</i> in 54 patients. Notably, <i>NKX3.1</i> loss without accompanying <i>LPL</i> deletion was observed in eight additional cases. These findings suggest that <i>LPL</i> deletion is a passenger event secondary to <i>NKX3.1</i> loss and underscore the importance of cautious interpretation of cytogenetic findings involving the <i>LPL</i> locus.

Authors

Institutions

Publication Details

Journal
Biomolecules
Published
2025-05-24
DOI
https://doi.org/10.3390/biom15060758
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deletions of LPL and NKX3.1 in Prostate Cancer Progression: Game Changers or By-Standers in Tumor Evolution

Jan Bouchal, Tereza Hulínová, Jana Schwarzerová, Jana Žmolíková et al.
Biomolecules
Prostate Cancer Treatment and Research
article

Deletions of LPL and NKX3.1 in Prostate Cancer Progression: Game Changers or By-Standers in Tumor Evolution

Jan Bouchal, Tereza Hulínová, Jana Schwarzerová, Jana Žmolíková, Michal Grepl, Mária Wozniaková, Vladimír Židlík, Jana Dvořáčková, Adéla Kondé
article en

Abstract

The tumor suppressor gene <i>NKX3</i>.1 and the <i>LPL</i> gene are located in close proximity on chromosome 8, and their deletion has been reported in multiple studies. However, the significance of <i>LPL</i> loss may be misinterpreted due to its co-deletion with <i>NKX3.1</i>, a well-established event in prostate carcinogenesis. This study investigates whether <i>LPL</i> deletion represents a biologically relevant event or occurs merely as a bystander to <i>NKX3.1</i> loss. We analyzed 28 formalin-fixed paraffin-embedded prostate cancer samples with confirmed <i>LPL</i> deletion and 28 without. Immunohistochemical staining was performed, and previously published whole-genome sequencing data from 103 prostate cancer patients were reanalyzed. Deletion of the 8p21.3 region was associated with higher Gleason grade groups. While NKX3.1 expression was significantly reduced in prostate cancer compared to benign prostatic hyperplasia, LPL protein expression showed no significant difference between cancerous and benign tissue, nor was it affected by the 8p21.3 deletion status. Copy number analysis confirmed the co-deletion of <i>NKX3.1</i> and <i>LPL</i> in 54 patients. Notably, <i>NKX3.1</i> loss without accompanying <i>LPL</i> deletion was observed in eight additional cases. These findings suggest that <i>LPL</i> deletion is a passenger event secondary to <i>NKX3.1</i> loss and underscore the importance of cautious interpretation of cytogenetic findings involving the <i>LPL</i> locus.

BiomoleculesVol. 15(6)
University of Vienna (AT), VSB - Technical University of Ostrava (CZ), University Hospital Ostrava (CZ), University Hospital Olomouc (CZ), Institute of Molecular and Translational Medicine (CZ), CGB Laboratory (CZ), Brno University of Technology (CZ), Palacký University Olomouc (CZ)
Ministerstvo Zdravotnictví Ceské Republiky
Good health and well-being
Openalex Percentile: Top 81%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.